LNAIHealthcare · Biotechnology

LNAI Stock Forecast: Lunai Bioworks, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$2.16

−1.82% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 22 Aug 2026 — in the lower half.

Market cap

$9.8M

Ticker Nerd rank

31 / 100

Median analyst target

—

Analysts covering

—

Total return, dividends reinvested

−2.7%

−21.7%

YTD

−69.4%

−88.2%

From 52W high

−89.5%

From 52W low

+46.7%

$21

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

LNAI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lunai Bioworks, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

31 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals

100

Size

Issuance

Growth

Volatility

Momentum

Revisions

Value

Quality

Accruals (100): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (8): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LNAI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LNAI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LNAI appears on the weeks it earns a place.

Estimates

LNAI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Lunai Bioworks, Inc. (LNAI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.0×
Price / sales: 466.6×
Price / book: −0.7×
EV / EBITDA: −0.8×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: 100.0%
Operating margin: −6815.3%
Net margin: 0.0%

Returns & dividend

Return on equity: −325.5%
Return on assets: −9.6%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LNAI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
LNAILunai Bioworks, Inc.	$9.8M	31
OSRHOSR Health, Inc.	$9.7M	24
SKYESkye Bioscience, Inc.	$9.8M	34
MTVAMetaVia, Inc.	$9.6M	17
FBLGFibroBiologics, Inc.	$9.6M	47
AEONAEON Biopharma, Inc.	$9.6M	48
IMNNImunon, Inc.	$9.2M	22

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lunai Bioworks, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LNAI news & analysis

Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027

PRNewsWire · 4 Aug 2026positive

Lunai Bioworks has signed a definitive collaboration agreement with BrainStorm Therapeutics, with initial Parkinson's disease data readout targeted for the first half of 2027. The executed Master Collaboration Agreement establishes an integrated roadmap spanning AI-driven patient stratification, human translational validation, biomarker development, and pharmaceutical partnering.

Why it matters — A LNAI watcher would care because the agreement establishes the company's integrated roadmap for its Parkinson's disease program and sets a target for initial clinical data readout in the first half of 2027.

Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit

PRNewsWire · 4 Aug 2026positive

Lunai Bioworks (Nasdaq: LNAI) amended its lawsuit naming 10 defendants in a naked short selling fraud suit, alleging 29.6 million failed-to-deliver shares and a single day trading volume 15.3 times shares outstanding. The company is seeking treble damages under the federal RICO statute.

Why it matters — A LNAI watcher would care because the company is taking legal action to address alleged trading manipulation affecting its shares.

FAQ

Frequently asked questions about LNAI stock

How does Ticker Nerd's model rank LNAI?

As at 22 Aug 2026, Lunai Bioworks, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (100 of 100).

What is the LNAI stock forecast for 2030?

No analyst covering Lunai Bioworks, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LNAI are extrapolating price history, which says nothing about the business.

How has LNAI stock performed over the past year?

Lunai Bioworks, Inc. returned -88.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lunai Bioworks, Inc. do?

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that develops medicine, diagnostics, and biodefense products.

What is the latest news on LNAI?

The most recent item we track (PRNewsWire, 4 Aug 2026): "Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027". Lunai Bioworks has signed a definitive collaboration agreement with BrainStorm Therapeutics, with initial Parkinson's disease data readout targeted for the first half of 2027. The executed Master Collaboration Agreement establishes an integrated roadmap spanning AI-driven patient stratification, human translational validation, biomarker development, and pharmaceutical partnering.

Company

About Lunai Bioworks, Inc.

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that develops medicine, diagnostics, and biodefense products. The company integrates artificial intelligence, genomics, and living biological systems to decode disease mechanisms and identify therapeutic targets. Its pipeline includes genetically modified dendritic cell therapeutic vaccines, such as RENB-DC11 for pancreatic cancer and RENB-DC20 for breast cancer treatment. Lunai Bioworks operates through multiple segments, including RENB, BioSymetrics, and RENC. The company employs proprietary AI platforms combined with zebrafish models to uncover drug efficacy, safety profiles, and clinical biomarkers that traditional research methods may overlook. By integrating phenotypic, proteomic, and genomic data, Lunai Bioworks aims to create clear pathways from disease discovery to patient benefit, focusing on precision medicine approaches for oncology and other therapeutic areas. Headquartered in Los Angeles, California, the company serves both the United States and Netherlands markets.

CEO Mr. David H. Weinstein · 29 employees · United States · https://www.lunaibioworks.com